EIP Pharma

EIP Pharma Overview

Founded 2014
Founded
Status Private
Employees 7
Employees
Latest Deal Type Later Stage VC
Latest Deal Amount $2.73M
Latest Deal Amount
Investors 5

EIP Pharma General Information

Description

Developer of a CNS-focused therapeutics intended to offer treatment for Alzheimer's Disease. The company's drug promotes recovery of function in patients suffering from acute neurologic injury, enabling doctors to treat brain diseases of Alzheimer's and other central nervous system drugs more effectively and improve episodic memory functions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
  • 120 St. James Avenue Floor 6
  • The Yard, Suite #6017
  • Cambridge, MA 02116
  • United States
+1 (617) 000-0000

EIP Pharma Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

EIP Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 23-Jan-2020 $2.73M 000.00 Completed Generating Revenue
5. Early Stage VC 15-Apr-2019 000.00 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 02-Apr-2018 000.00 000.00 0000 Completed Clinical Trials - Phase 2
3. Angel (individual) 06-Jan-2017 00000 00.00 Completed Clinical Trials - Phase 2
2. Angel (individual) 01-Jan-2017 $4.2M $5.7M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A1) 01-Oct-2016 $1.5M $1.5M Completed Clinical Trials - Phase 2

EIP Pharma Cap Table

To view EIP Pharma‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A2 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A1 17,033,883 $0.001000 $0.09 $0.09 1x $0.09 48.55%

EIP Pharma Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
ProMIS Neurosciences Corporation Toronto, Canada 0 000.00 000000000 000.00
00000000 000000000 Venture Capital-Backed Boston, MA 00 00000 00000000000 00000
000000000 00000000 Venture Capital-Backed Cambridge, MA 00 000.00 0000000000 0 000.00
000000 00000000000 Venture Capital-Backed Cambridge, MA 0 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed Cambridge, MA 0000 00000000000 0000

EIP Pharma Executive Team (4)

Name Title Board Seat Contact Info
John Alam MD Co-Founder, President, Chief Executive Officer & Board Member
Noel Donnelly Chief Financial Officer
Kevin Sarney Vice President of Finance and Administration
Sylvie Grégoire Co-Founder & Executive Chairman

EIP Pharma Board Members (5)

Name Representing Role Since
Frank Zavrl Self Board Member 000 0000
Jeffrey Poulton Self Board Member 000 0000
John Alam MD EIP Pharma Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Sylvie Grégoire Self Co-Founder & Executive Chairman 000 0000
Tatjana May EIP Pharma Board Member 000 0000

EIP Pharma Investors (5)

To view EIP Pharma‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adage Capital Management Hedge Fund Minority 000 0000 000000 0
Mossrock Capital Other Minority 000 0000 000000 0
Rock Springs Capital Hedge Fund Minority 000 0000 000000 0
Access Industries Corporation Minority 000 0000 000000 0
Founders Fund Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial